Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody–associated Vasculitis

REFERENCES

1. 1.↵
   1. Schonermarck U,
   2. Csernok E,
   3. Gross WL

   . Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014. Nephrol Dial Transplant 2015;30 Suppl 1:i46–52.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Chen M,
   2. Jayne DR,
   3. Zhao MH

   . Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol 2017;13:359–67.

   OpenUrl
3. 3.↵
   1. Xiao H,
   2. Schreiber A,
   3. Heeringa P,
   4. Falk RJ,
   5. Jennette JC

   . Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52–64.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Schreiber A,
   2. Xiao H,
   3. Jennette JC,
   4. Schneider W,
   5. Luft FC,
   6. Kettritz R

   . C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289–98.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Charles Jennette J,
   2. Xiao H,
   3. Hu P

   . Complement in ANCA-associated vasculitis. Semin Nephrol 2013;33:557–64.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Gou SJ,
   2. Yuan J,
   3. Wang C,
   4. Zhao MH,
   5. Chen M

   . Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 2013;8:1884–91.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Villacorta J,
   2. Diaz-Crespo F,
   3. Acevedo M,
   4. Guerrero C,
   5. Campos-Martin Y,
   6. García-Díaz E,
   7. et al.

   Glomerular C3d as a novel prognostic marker for renal vasculitis. Hum Pathol 2016;56:31–9.

   OpenUrl
8. 8.↵
   1. Hilhorst M,
   2. van Paassen P,
   3. van Rie H,
   4. Bijnens N,
   5. Heerings-Rewinkel P,
   6. van Breda Vriesman P,
   7. et al;
   8. Limburg Renal Registry

   . Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2017;32:1302–13.

   OpenUrl
9. 9.↵
   1. Jayne DRW,
   2. Bruchfeld AN,
   3. Harper L,
   4. Schaier M,
   5. Venning MC,
   6. Hamilton P,
   7. et al;
   8. CLEAR Study Group

   . Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017;28:2756–67.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Laumonnier Y,
    2. Karsten CM,
    3. Kohl J

    . Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol Immunol 2017;89:44–58.

    OpenUrl
11. 11.↵
    1. Merle NS,
    2. Church SE,
    3. Fremeaux-Bacchi V,
    4. Roumenina LT

    . Complement system part I – molecular mechanisms of activation and regulation. Front Immunol 2015;6:262.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Kourtzelis I,
    2. Markiewski MM,
    3. Doumas M,
    4. Rafail S,
    5. Kambas K,
    6. Mitroulis I,
    7. et al.

    Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010;116:631–9.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Coulthard LG,
    2. Woodruff TM

    . Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol 2015;194:3542–8.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Banda NK,
    2. Hyatt S,
    3. Antonioli AH,
    4. White JT,
    5. Glogowska M,
    6. Takahashi K,
    7. et al.

    Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 2012;188:1469–78.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Chen NJ,
    2. Mirtsos C,
    3. Suh D,
    4. Lu YC,
    5. Lin WJ,
    6. McKerlie C,
    7. et al.

    C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007;446:203–7.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Distler JH,
    2. Huber LC,
    3. Gay S,
    4. Distler O,
    5. Pisetsky DS

    . Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 2006;39:683–90.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Burger D,
    2. Schock S,
    3. Thompson CS,
    4. Montezano AC,
    5. Hakim AM,
    6. Touyz RM

    . Microparticles: biomarkers and beyond. Clin Sci 2013;124:423–41.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. György B,
    2. Szabó TG,
    3. Pásztói M,
    4. Pál Z,
    5. Misják P,
    6. Aradi B,
    7. et al.

    Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011;68:2667–88.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Brogan PA,
    2. Shah V,
    3. Brachet C,
    4. Harnden A,
    5. Mant D,
    6. Klein N,
    7. et al.

    Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 2004;50:927–36.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Erdbruegger U,
    2. Grossheim M,
    3. Hertel B,
    4. Wyss K,
    5. Kirsch T,
    6. Woywodt A,
    7. et al.

    Diagnostic role of endothelial microparticles in vasculitis. Rheumatology 2008;47:1820–5.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Daniel L,
    2. Fakhouri F,
    3. Joly D,
    4. Mouthon L,
    5. Nusbaum P,
    6. Grunfeld JP,
    7. et al.

    Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 2006;69:1416–23.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Hong Y,
    2. Eleftheriou D,
    3. Hussain AA,
    4. Price-Kuehne FE,
    5. Savage CO,
    6. Jayne D,
    7. et al.

    Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol 2012;23:49–62.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Mesri M,
    2. Altieri DC

    . Endothelial cell activation by leukocyte microparticles. J Immunol 1998;161:4382–7.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Pitanga TN,
    2. de Aragão França L,
    3. Rocha VC,
    4. Meirelles T,
    5. Borges VM,
    6. Goncalves MS,
    7. et al.

    Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells. BMC Cell Biol 2014;15:21.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Watts R,
    2. Lane S,
    3. Hanslik T,
    4. Hauser T,
    5. Hellmich B,
    6. Koldingsnes W,
    7. et al.

    Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–7.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Yates M,
    2. Watts RA,
    3. Bajema IM,
    4. Cid MC,
    5. Crestani B,
    6. Hauser T,
    7. et al.

    EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583–94.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Levey AS,
    2. Coresh J,
    3. Greene T,
    4. Stevens LA,
    5. Zhang YL,
    6. Hendriksen S,
    7. et al;
    8. Chronic Kidney Disease Epidemiology Collaboration

    . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–54.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Aratani Y

    . Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys 2018;640:47–52.

    OpenUrlCrossRef
29. 29.↵
    1. van der Veen BS,
    2. de Winther MP,
    3. Heeringa P

    . Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009;11:2899–937.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Kambas K,
    2. Chrysanthopoulou A,
    3. Vassilopoulos D,
    4. Apostolidou E,
    5. Skendros P,
    6. Girod A,
    7. et al.

    Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2014;73:1854–63.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Huang YM,
    2. Wang H,
    3. Wang C,
    4. Chen M,
    5. Zhao MH

    . Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol 2015;67:2780–90.

    OpenUrl
32. 32.↵
    1. Biró E,
    2. Nieuwland R,
    3. Tak PP,
    4. Pronk LM,
    5. Schaap MC,
    6. Sturk A,
    7. et al.

    Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2007;66:1085–92.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Nielsen CT,
    2. Østergaard O,
    3. Stener L,
    4. Iversen LV,
    5. Truedsson L,
    6. Gullstrand B,
    7. et al.

    Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus. Arthritis Rheum 2012;64:1227–36.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Mobarrez F,
    2. Vikerfors A,
    3. Gustafson JT,
    4. Gunnarsson I,
    5. Zickert A,
    6. Larsson A,
    7. et al.

    Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. Sci Rep 2016;6:36025.

    OpenUrl
35. 35.↵
    1. Gou SJ,
    2. Yuan J,
    3. Chen M,
    4. Yu F,
    5. Zhao MH

    . Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013;83:129–37.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Xing GQ,
    2. Chen M,
    3. Liu G,
    4. Heeringa P,
    5. Zhang JJ,
    6. Zheng X,
    7. et al.

    Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009;29:282–91.

    OpenUrlCrossRefPubMed